New atopic dermatitis drugs are currently being considered for expanded use in infants and young children.

First, Sanofi Korea's 'Dupixent (dupilumab)' will be reimbursed for treating infants aged 6 months beginning next month. The company has recently concluded the drug price negotiation, and on July 19th, Dupixent was incorporated into the Ministry of Health and Welfare (MOHW)'s revised regulations on the criteria and scope of National Health Insurance.

Dupixent's expanded reimbursement for young children was in high demand. Previously, the Severe Atopic Dermatitis Association (SADA) issued a statement urging the coverage of Dupixent for young children aged 6 months to younger than 6